The combined drug “Simbikort” and its role in bronchial asthma therapy

1. Бронхиальная астма. Глобальная стратегия: совместный доклад Национального института Сердце, Легкие, Кровь и Всемирной организации здравоохранения. Русская версия под общ. ред. акад. А.Г.Чучалина. Пульмонология, 1996; прил.:1 — 165.

2. Бронхиальная астма. Руководство для врачей России (формулярная система). Там же, 1999; прил.: 1—40.

3. Калманова Е.Н., Айсанов З.Р. Форадил и его место в терапии бронхиальной астмы. Там же, 2001; 1: 65—72.

4. Формулярная система: лечение бронхиальной астмы. Астма.ru 0. 2001; 6—9.

5. Чучалин А.Г. Бронхиальная астма. М.; 1997, т.1—2.

6. Agertoft L., Pedersen S. Effect of long-term treatment with inhaled biidesonide on adult height in children with asthma. N. Engl. J. Med. 2000; 343: 1064—1069.

7. Andersson F. et al. The costs and effects of adding formoterol to budesonide — results of the FACET Study. Am. J. Respir. Crit. Care Med. 1999; 159 (3, Pt.2): A762.

8. Anderson G.P. Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of highly potent and selective agonist bronchodilatator. Life Sei. 1993; 52: 2145—2160.

9. Ankerst J., Persson G., Weibull E. A high dose of budesonide/formoterol in a single inhaler was well tolerated by asthmatic patients. Eur. Respir. J. 2000; 16 (suppl.31): 33s+poster.

10. Barney P.G.J. Current questions in the epidemiology of asthma. In: Holgate S.Т., et al. Asthma: Physiology. Immunology, and Treatment. London: Academic Press; 1993. 3—25.

11. Crisholm S. et al. Once-daily budesonide in mild asthma. Respir. Med. 1998; 92: 421—425.

12. Juniper E.F., Svensson K., Byrne P.M. et al. Asthma quality of life during 1 year of treatment with budesonide with or without formoterol. Eur. Respir. J. 1999; 14: 1038—1043.

13. Kips J.C., O’Connor B.J., Inman M.D. et al. A long-termed study of the antiinflammatory effect of low-dosed budesonide plus formoterol versus high-dosed budesonide in asthma. Am. Respir. Crit. Care Med. 2000; 161: 996—1001.

14. McFadden E.R., Casale T.B., Edwards T.B. et al. Administration of budesonide once daily by means of Turbuhaler to subjects with stable asthma. J. Allergy Clin. Immunol. 1999; 104: 46—52.

15. Miller-Larsson A. et. al. Prolonged airway activity and improved selectivity of budesonide possibly due to esterification. Am. J. Respir. Crit. Care Med. 2000; 162: 1455—1461.

16. Miller-Larsson A., Mattsson H., Hjertberg E., et al. Reversible fatty acid conjugation of budesonide: novel mechanism foe prolonged retention of topically applied steroid in airway tissue. Drug Metab. Dispos. 1998; 26: 623—630.

17. Molimard M. et al. Long- and short-adrenoreceptor agonists: interactions in human contracted bronchi. Eur. Respir. J. 1998; 11: 583—588.

18. O’Connor B.J., Alkinan S.L., Barnes P.J. Tolerance to the non-bronchodilatator effects of inhaled ß2-agonists in asthma. N. Engl. J. Med. 1992; 327: 1204—1208.

19. Palmquist M. et al. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am. J. Respir. Crit. Care Med. 1999; 160: 244—249.

20. Palmquist M. et al. Inhaled dry powder formoterol and salmererol in asthmatic patients: onset of action, duration of effect and potency. Eur. Respir. J. 1997; 10: 2484—2489.

21. Pauwels R.A. et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N. Engl. J. Med. 1997; 337: 1405—1411.

22. Pedersen S., O’Byrne P. A comparison of the efficacy and safety of inhaled corticosteroides in asthma. Allergy 1997; 52 (suppl.39): 1—34.

23. Politiek M.J., Boorsma M., Aalbers R. Comparison of formoterol, salbutamol and salmeterol in methacholine-induced severe bronchoconstriction. Eur. Respir. J. 1999; 13: 988—992.

24. The British Guidelines on Asthma Management. Thorax, 1997; 52 (suppl.l): 1—20.

25. Woolcock A. et al. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am. J. Respir. Crit. Care Med. 1996; 153: 1481—1488.